898 related articles for article (PubMed ID: 10382947)
21. Is veno-occlusive disease incidence influenced by the total-body irradiation technique?
Belkacémi Y; Ozsahin M; Rio B; Laporte JP; Leblond V; Pène F; Laugier A
Strahlenther Onkol; 1995 Dec; 171(12):694-7. PubMed ID: 8545791
[TBL] [Abstract][Full Text] [Related]
22. Addition of high-dose Ara-C to the BMT conditioning regimen reduces leukemia relapse without an increase in toxicity.
Mineishi S; Longo WL; Atkinson ME; Smith EP; Hamielec M; Wiersma SR; Kinsella TJ; Schuening FG
Bone Marrow Transplant; 1999 Jun; 23(12):1217-22. PubMed ID: 10414906
[TBL] [Abstract][Full Text] [Related]
23. High-dose cytosine arabinoside and fractionated total body irradiation as a preparative regimen for the treatment of children with acute lymphoblastic leukemia and Down syndrome by allogeneic bone marrow transplantation.
Conter V; D'Angelo P; Rizzari C; Jankovic M; Dampier C; Masera G; Johnson FL
Bone Marrow Transplant; 1996 Feb; 17(2):287-9. PubMed ID: 8640182
[TBL] [Abstract][Full Text] [Related]
24. High-dose cytosine arabinoside and etoposide with total body irradiation as a preparatory regimen for allogeneic hematopoietic stem-cell transplantation in patients with acute lymphoblastic leukemia.
Sato N; Furukawa T; Kuroha T; Hashimoto S; Masuko M; Takahashi H; Yano T; Abe T; Fuse I; Koike T; Kishi K; Aizawa Y
Bone Marrow Transplant; 2004 Aug; 34(4):299-303. PubMed ID: 15195078
[TBL] [Abstract][Full Text] [Related]
25. Long-term follow-up of allogeneic hematopoietic stem cell transplantation for de novo acute myelogenous leukemia with a conditioning regimen of total body irradiation and granulocyte colony-stimulating factor-combined high-dose cytarabine.
Mori T; Aisa Y; Watanabe R; Yamazaki R; Kato J; Shimizu T; Shigematsu N; Kubo A; Yajima T; Hibi T; Ikeda Y; Okamoto S
Biol Blood Marrow Transplant; 2008 Jun; 14(6):651-7. PubMed ID: 18489990
[TBL] [Abstract][Full Text] [Related]
26. Dose-dependent effect of etoposide in combination with busulfan plus cyclophosphamide as conditioning for stem cell transplantation in patients with acute myeloid leukemia.
Kröger N; Zabelina T; Sonnenberg S; Krüger W; Renges H; Stute N; Finkenstein F; Mayer U; Holstein K; Fiedler W; Colberg H; Sonnen R; Kuse R; Braumann D; Metzner B; del Valle F; Erttmann R; Kabisch H; Zander AR
Bone Marrow Transplant; 2000 Oct; 26(7):711-6. PubMed ID: 11042650
[TBL] [Abstract][Full Text] [Related]
27. Sequential intensified conditioning and tapering of prophylactic immunosuppressants for graft-versus-host disease in allogeneic hematopoietic stem cell transplantation for refractory leukemia.
Liu QF; Fan ZP; Zhang Y; Jiang ZJ; Wang CY; Xu D; Sun J; Xiao Y; Tan H
Biol Blood Marrow Transplant; 2009 Nov; 15(11):1376-85. PubMed ID: 19822296
[TBL] [Abstract][Full Text] [Related]
28. A study of thiotepa, etoposide and fractionated total body irradiation as a preparative regimen prior to bone marrow transplantation for poor prognosis patients with neuroblastoma.
Kamani N; August CS; Bunin N; Leahey A; Bayever E; Goldwein J; Zusman J; Evans AE; Angio GD
Bone Marrow Transplant; 1996 Jun; 17(6):911-6. PubMed ID: 8807093
[TBL] [Abstract][Full Text] [Related]
29. [Hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia].
Liu QF; Sun J; Zhang Y; Liu XL; Xu D; Xu B; Feng R; Meng FY; Zhou SY
Ai Zheng; 2004 Apr; 23(4):426-9. PubMed ID: 15087032
[TBL] [Abstract][Full Text] [Related]
30. Allogeneic matched T-cell-depleted bone marrow transplantation for acute leukemia patients.
Aristei C; Aversa F; Raymondi C; Marsella AR; Panizza BM; Perrucci E; Piro F; Maranzano E; Lupattelli M; Martelli MF; Latini P
Cancer J Sci Am; 1996; 2(6):330-4. PubMed ID: 9166553
[TBL] [Abstract][Full Text] [Related]
31. Influence of the conditioning regimen on erythrocyte chimerism, graft-versus-host disease and relapse after allogeneic transplantation with lymphocyte depleted marrow.
Bär BM; Schattenberg A; De Man AJ; Hoogenhout MJ; Boezeman J; de Witte T
Bone Marrow Transplant; 1992 Jul; 10(1):45-52. PubMed ID: 1515878
[TBL] [Abstract][Full Text] [Related]
32. Significance of additional high-dose cytarabine in combination with cyclophosphamide plus total body irradiation regimen for allogeneic stem cell transplantation.
Inamoto Y; Nishida T; Suzuki R; Miyamura K; Sao H; Iida H; Naoe T; Maruyama F; Hirabayashi N; Hamaguchi M; Iseki T; Kami M; Yano K; Takeyama H; Morishita Y; Morishima Y; Kodera Y
Bone Marrow Transplant; 2007 Jan; 39(1):25-30. PubMed ID: 17115063
[TBL] [Abstract][Full Text] [Related]
33. Melphalan-total body irradiation and autologous bone marrow transplantation for adult acute leukemia beyond first remission.
Mehta J; Powles R; Singhal S; Horton C; Tait D; Treleaven J
Bone Marrow Transplant; 1996 Jul; 18(1):119-23. PubMed ID: 8832004
[TBL] [Abstract][Full Text] [Related]
34. Excellent outcome of allogeneic hematopoietic stem cell transplantation using a conditioning regimen with medium-dose VP-16, cyclophosphamide and total-body irradiation for adult patients with acute lymphoblastic leukemia.
Shigematsu A; Kondo T; Yamamoto S; Sugita J; Onozawa M; Kahata K; Endo T; Shiratori S; Ota S; Obara M; Wakasa K; Takahata M; Takeda Y; Tanaka J; Hashino S; Nishio M; Koike T; Asaka M; Imamura M
Biol Blood Marrow Transplant; 2008 May; 14(5):568-75. PubMed ID: 18410899
[TBL] [Abstract][Full Text] [Related]
35. Allogeneic bone marrow transplantation in high-risk myeloid disorders using busulfan, cytosine arabinoside and cyclophosphamide (BAC).
Ratanatharathorn V; Karanes C; Lum LG; Uberti J; Dan ME; de Planque MM; Schultz KR; Cronin S; Leisz MC; Mohamed A
Bone Marrow Transplant; 1992 Jan; 9(1):49-55. PubMed ID: 1543949
[TBL] [Abstract][Full Text] [Related]
36. Role of splenic irradiation in patients with chronic myeloid leukemia undergoing allogeneic bone marrow transplantation.
Jabro G; Koc Y; Boyle T; Schenkein DP; Ravalese J; Wazer D; Miller KB
Biol Blood Marrow Transplant; 1999; 5(3):173-9. PubMed ID: 10392963
[TBL] [Abstract][Full Text] [Related]
37. Busulfan, cyclophosphamide and total body irradiation as conditioning for allogeneic bone marrow transplantation for acute and chronic myeloid leukemia.
Hirabayashi N; Goto S; Ishii M; Yuge M; Mitsuma A; Noda N
Bone Marrow Transplant; 1998 Jun; 21(11):1079-83. PubMed ID: 9645568
[TBL] [Abstract][Full Text] [Related]
38. Allogeneic transplantation for recurrent or refractory non-Hodgkin's lymphoma with poor prognostic features after conditioning with thiotepa, busulfan, and cyclophosphamide: experience in 44 consecutive patients.
van Besien K; Thall P; Korbling M; Pugh WC; Khouri I; Mehra R; Giralt S; Anderlini P; Amin K; Mirza N; Seong D; Gajewski J; Hester J; Andersson B; Cabanillas F; Champlin R; Przepiorka D
Biol Blood Marrow Transplant; 1997 Aug; 3(3):150-6. PubMed ID: 9310192
[TBL] [Abstract][Full Text] [Related]
39. Outcome of second bone marrow transplantation following a uniform conditioning regimen as therapy for malignant relapse.
Chiang KY; Weisdorf DJ; Davies SM; Enright H; Kersey JH; McGlave PB; Miller W; Ramsay NK; Steinbuch M; Wagner JE; Blazar BR
Bone Marrow Transplant; 1996 Jan; 17(1):39-42. PubMed ID: 8673052
[TBL] [Abstract][Full Text] [Related]
40. Modified conditioning regimen busulfan-cyclophosphamide followed by allogeneic stem cell transplantation in patients with multiple myeloma.
Zhang XH; Huang XJ; Liu KY; Xu LP; Liu DH; Chen H; Chen YH; Wang JZ; Han W; Lu DP
Chin Med J (Engl); 2007 Mar; 120(6):463-8. PubMed ID: 17439737
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]